The goal of the BALANCE+ clinical trial is to transform random care to randomized care for patients with Gram negative bloodstream infections to inform best treatment approaches and optimize outcomes. BALANCE+, a perpetual platform trial, will efficiently answer multiple questions that are important for hospitalized patients with Gram negative bloodstream infections.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Recruitment rate (co-primary outcomes of BALANCE+ vanguard phase)
Timeframe: 1 year
Protocol adherence (co-primary outcomes of BALANCE+ vanguard phase)
Timeframe: 1 year
De-escalation versus no de-escalation domain
Timeframe: 90 days
Oral beta-lactam versus non beta-lactam domain
Timeframe: 90 days
Central vascular catheter retention versus replacement domain
Timeframe: 90 days
Low-risk AmpC domain
Timeframe: 90 days
Follow-up blood culture domain
Timeframe: 90 days